Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Down 42.7% in March

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a significant drop in short interest in the month of March. As of March 13th, there was short interest totaling 109,555 shares, a drop of 42.7% from the February 26th total of 191,156 shares. Based on an average trading volume of 152,358 shares, the days-to-cover ratio is presently 0.7 days. Currently, 5.4% of the shares of the company are sold short.

Analyst Ratings Changes

MBRX has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Finally, Roth Mkm restated a “buy” rating on shares of Moleculin Biotech in a research note on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Trading Up 0.4%

NASDAQ MBRX traded up $0.01 on Friday, hitting $2.44. 82,210 shares of the company’s stock were exchanged, compared to its average volume of 130,126. The stock has a 50-day moving average of $3.22 and a 200-day moving average of $6.79. The stock has a market cap of $13.03 million, a price-to-earnings ratio of -0.07 and a beta of 1.73. Moleculin Biotech has a 52 week low of $1.79 and a 52 week high of $28.61.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech at the end of the most recent quarter. Institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.